Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 552-554
DOI: 10.4103/ijmpo.ijmpo_81_20
Drug Review

Ivosidenib – Another Feather in the Hat of Treatment for Acute Myeloid Leukemia

Contributor(s):
Jayachandran Perumal Kalaiyarasi
Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

The treatment of acute myeloid leukemia has undergone a paradigm shift in the past few years. Multiple new targeted and nontargeted agents have been approved in the recent past. Isocitrate dehydrogenase (IDH) mutation is one such target that has been identified, and two new drugs, ivosidenib and enasidenib have been approved. The former is an IDH1 inhibitor, and the latter is an IDH2 inhibitor. The mechanism of action, key trials, adverse events, and monitoring of ivosidenib has been discussed in this article.

Keywords

Isocitrate dehydrogenase inhibitors - ivosidenib - new drugs in acute myeloid leukemia


Publication History

Received: 26 February 2020

Accepted: 03 May 2020

Article published online:
17 May 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA. et al. Acute myeloid leukaemia: Challenges and real world data from India. Br J Haematol 2015; 170: 110-7
    CrossrefPubMedGoogle Scholar
  • 2 Kalaiyarasi JP, Ganesan P, Kannan K, Ganesan TS, Radhakrishnan V, Dhanushkodi M. et al. Outcomes of intensive treatment of adult acute myeloid leukemia patients: A retrospective study from a single centre. Indian J Hematol Blood Transfus 2019; 35: 248-54
    CrossrefPubMedGoogle Scholar
  • 3 Pant M, Bhatt VR. Early mortality and survival in older adults with acute myeloid leukemia. Int J Hematol Oncol 2017; 6: 61-3
    CrossrefPubMedGoogle Scholar
  • 4 Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P. IDH1-mutated relapsed or refractory AML: Current challenges and future prospects. Blood Lymphat Cancer Targets Ther 2019; 9: 19-32
    CrossrefPubMedGoogle Scholar
  • 5 Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ. et al. Acute myeloid leukemia with IDH1 or IDH2 mutations: Frequency and clinicopathologic features. Am J Clin Pathol 2011; 135: 35-45
    CrossrefPubMedGoogle Scholar
  • 6 DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T. et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol 2015; 90: 732-6
    CrossrefPubMedGoogle Scholar
  • 7 Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation-Full Text View-ClinicalTrials. https://clinicaltrials.gov/ct2/show/NCT02074839 Available from: [Last accessed on 2020 Feb 26]
    Google Scholar
  • 8 DiNardo CD, Stein EM, Botton Sde, Roboz GJ, Altman JK, Mims AS. et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018; 378: 2386-98
    CrossrefPubMedGoogle Scholar
  • 9 Prior DJ. A study of the electrophysiological properties of the incurrent siphonal valve muscle of the surf clam, Spisula solidissima. Comp Biochem Physiol A Comp Physiol 1975; 52: 607-10
    CrossrefPubMedGoogle Scholar
  • 10 Study of AG-120 (Ivosidenib) vs. Placebo in Combination with Azacitidine in Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation-Full Text View-ClinicalTrials. https://clinicaltrials.gov/ct2/show/NCT03173248 Available from: [Last accessed on 2020 Feb 26]
    Google Scholar
  • 11 IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-Mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation-Full Text View-ClinicalTrials. https://clinicaltrials.gov/ct2/show/NCT03564821 Available from: [Last accessed on 2020 Feb 26]
    Google Scholar
  • 12 Birendra K, DiNardo CD. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymphoma Myeloma Leuk 2016; 16: 460-5
    CrossrefPubMedGoogle Scholar
  • 13 Highlights of Prescribing Information-Tibsovo® (Ivosidenib Tablets), for Oral Use; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf
    Google Scholar
  • 14 Fan B, Mellinghoff IK, Wen PY, Lowery MA, Goyal L, Tap WD. et al. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Invest New Drugs 2020; 38: 433-44
    CrossrefPubMedGoogle Scholar